T he American College of Cardiology/American Heart Association (ACC/AHA) Guidelines for the Management of Patients With Acute Myocardial Infarction have been reviewed over the past 2.5 years since their initial publication in the Journal of the American College of Cardiology (1996; 28:1328 -1428 to ensure their continued relevancy. The guidelines have been updated to include the most significant advances that have occurred in the management of patients with acute myocardial infarction (AMI) during that time frame. This update was developed to keep the guidelines current without republishing the entire document. This effort represents a new procedure of the ACC/AHA Task Force on Practice Guidelines. These guidelines will be reviewed and updated as necessary until it is deemed appropriate to revise and republish the entire document.
The guidelines, incorporating the update, are available on the Web sites of both the American College of Cardiology (www.acc.org) and the American Heart Association (www.americanheart.org). In the Web site version, deleted text is indicated by strikeout, and new/revised text is presented as double-underlined type. Reprints of the original document with the revised sections appended are available from both organizations (see information below).
Recommendations
The following is a listing of the recommendations made by the ACC/AHA Task Force on Practice Guidelines in the ACC/AHA Task Force Report "ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction." More detailed information regarding the evidence and the rationale for these recommendations can be found in the full text of the guidelines themselves, which appears in the November 1996 and September 1999 (update) issues of the Journal of the American College of Cardiology.
Explanation of Classes
As in previous guidelines, the American College of Cardiology and the American Heart Association have used the following classification system in which indications for a diagnostic procedure, a particular therapy, or intervention are designated as: Class I: Conditions for which there is evidence for and/or general agreement that a given procedure or treatment is beneficial, useful, and effective. 
Early Coronary Angiography in the ST-Segment Elevation or BBB Cohort Not Undergoing Primary PTCA

Class I
None.
Class IIa
1. Patients with cardiogenic shock or persistent hemodynamic instability.
Class IIb
1. Patients with evolving large or anterior infarcts treated with thrombolytic agents in whom it is believed that the artery is not patent and adjuvant PTCA is planned.
Class III
1. Routine use of angiography and subsequent PTCA within 24 hours of administration of thrombolytic agents.
Emergency or Urgent Coronary Artery Bypass Graft (CABG) Surgery
Class I
1. Failed angioplasty with persistent pain or hemodynamic instability in patients with coronary anatomy suitable for surgery. 2. AMI with persistent or recurrent ischemia refractory to medical therapy in patients with coronary anatomy suitable for surgery who are not candidates for catheter intervention.
3. At the time of surgical repair of postinfarction ventricular septal defect (VSD) or mitral valve insufficiency.
Class IIa
1. Cardiogenic shock with coronary anatomy suitable for surgery.
Class IIb
1. Failed PTCA and small area of myocardium at risk; hemodynamically stable.
Class III
1. When the expected surgical mortality rate equals or exceeds the mortality rate associated with appropriate medical therapy. 
Early Coronary Angiography and/or Interventional Therapy in Non-ST-Segment Elevation Cohort
Intra-arterial Pressure Monitoring
Class I 
Class III
1. Patients with acute infarction who are hemodynamically stable.
Intra-aortic Balloon Counterpulsation
Class I
1. Cardiogenic shock not quickly reversed with pharmacological therapy as a stabilizing measure for angiography and prompt revascularization.
2. Acute mitral regurgitation or VSD complicating MI as a stabilizing therapy for angiography and repair/revascularization. 3. Recurrent intractable ventricular arrhythmias with hemodynamic instability. 4. Refractory post-MI angina as a bridge to angiography and revascularization.
Class IIa
1. Signs of hemodynamic instability, poor LV function, or persistent ischemia in patients with large areas of myocardium at risk.
Class IIb
1. In patients with successful PTCA after failed thrombolysis or those with three-vessel coronary disease to prevent reocclusion.
2. In patients known to have large areas of myocardium at risk with or without active ischemia.
Rhythm Disturbances Atrial Fibrillation
Class I 1. Electrical cardioversion for patients with severe hemodynamic compromise or intractable ischemia. 2. Rapid digitalization to slow a rapid ventricular response and improve LV function. 3. Intravenous ␤-adrenoceptor blockers to slow a rapid ventricular response in patients without clinical LV dysfunction, bronchospastic disease, or AV block.
4. Heparin should be given.
Class IIa
1. Either diltiazem or verapamil intravenously to slow a rapid ventricular response if ␤-adrenoceptor blocking agents are contraindicated or ineffective.
Ventricular Tachycardia/Ventricular Fibrillation
Class I
1. Ventricular fibrillation (VF) should be treated with an unsynchronized electric shock with an initial energy of 200 J; if unsuccessful, a second shock of 200 to 300 J should be given, and, if necessary, a third shock of 360 J.
2. Sustained (more than 30 seconds or causing hemodynamic collapse) polymorphic ventricular tachycardia (VT) should be treated with an unsynchronized electric shock using an initial energy of 200 J; if unsuccessful, a second shock of 200 to 300 J should be given, and, if necessary, a third shock of 360 J.
3. Episodes of sustained monomorphic VT associated with angina, pulmonary edema, or hypotension (blood pressure less than 90 mm Hg) should be treated with a synchronized electric shock of 100 J initial energy. Increasing energies may be used if not initially successful.
4. Sustained monomorphic VT not associated with angina, pulmonary edema, or hypotension (blood pressure less than 90 mm Hg) should be treated with one of the following regimens: a. Lidocaine: bolus 1.0 to 1.5 mg/kg. Supplemental boluses of 0.5 to 0.75 mg/kg every 5 to 10 minutes to a maximum of 3 mg/kg total loading dose may be given as needed. Loading is followed by infusion of 2 to 4 mg/min (30 to 50 g/kg per minute).
b. Procainamide: 20 to 30 mg/min loading infusion, up to 12 to 17 mg/kg. This may be followed by an infusion of 1 to 4 mg/min. c. Amiodarone: 150 mg infused over 10 minutes followed by a constant infusion of 1.0 mg/min for 6 hours and then a maintenance infusion of 0.5 mg/min. d. Synchronized electrical cardioversion starting at 50 J (brief anesthesia is necessary).
Class IIa
1. Infusions of antiarrhythmic drugs may be used after an episode of VT/VF but should be discontinued after 6 to 24 hours and the need for further arrhythmia management assessed.
2. Electrolyte and acid-base disturbances should be corrected to prevent recurrent episodes of VF when an initial episode of VF has been treated.
Class IIb
1. Drug-refractory polymorphic VT should be managed by aggressive attempts to reduce myocardial ischemia, including therapies such as ␤-adrenoceptor blockade, intra-aortic balloon pumping, and emergency PTCA/CABG surgery. Amiodarone, 150 mg infused over 10 minutes followed by a constant infusion of 1.0 mg/min for up to 6 hours and then a maintenance infusion of 0.5 mg/min may also be helpful.
Class III
1. Treatment of isolated ventricular premature beats, couplets, runs of accelerated idioventricular rhythm, and nonsustained VT. 2. Prophylactic administration of antiarrhythmic therapy when using thrombolytic agents.
Bradyarrhythmias and Heart Block
Atropine
Class I
1. Symptomatic sinus bradycardia (generally, heart rate less than 50 bpm associated with hypotension, ischemia, or escape ventricular arrhythmia).
2. Ventricular asystole. 3. Symptomatic AV block occurring at the AV nodal level (second-degree type I or third-degree with a narrow-complex escape rhythm).
Class IIa
Class III
1. AV block occurring at an infranodal level (usually associated with anterior MI with a wide-complex escape rhythm). 2. Asymptomatic sinus bradycardia.
Temporary Pacing
Placement of Transcutaneous Patches* and Active (Demand) Transcutaneous Pacing † Class I
␤-Adrenoceptor Blocking Agents
Early Therapy
